DnaJ heat shock protein family (Hsp40) member B13Genealiases: CILD34 · RSPH16A · TSARG5 · TSARG6
Q-omics provides the consensus-scored DNAJB13 profile across patient tissues and cancer cell-line models. DNAJB13 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, DNAJB13 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, DNAJB13 RNA expression shows 17,371 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where DNAJB13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNAJB13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNAJB13 survival associations across molecular data types. DNAJB13 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNAJB13 RNA expression–survival associations across cancer types. High DNAJB13 expression shows unfavorable associations in UVM, LGG, ACC, LIHC and KIRC, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for DNAJB13 RNA expression.
This table summarizes DNAJB13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DNAJB13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNAJB13 shows lower tumor expression in KICH and LUSC and higher tumor expression in KIRC, KIRP, BLCA and BRCA. The KIRC box plot shows higher DNAJB13 RNA expression in tumor versus normal tissue (log2 FC = +2.043, t-test p < 0.001).
This table shows molecular features associated with DNAJB13 in patient tissues and cancer cell lines. In patient samples, DNAJB13 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, DNAJB13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
